PFG Investments LLC Makes New Investment in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

PFG Investments LLC purchased a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 189,030 shares of the company’s stock, valued at approximately $1,541,000. PFG Investments LLC owned approximately 0.34% of Ginkgo Bioworks as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in DNA. Wellington Wealth Strategies LLC. bought a new position in Ginkgo Bioworks during the second quarter worth about $41,000. Algert Global LLC acquired a new stake in shares of Ginkgo Bioworks during the second quarter worth about $36,000. Mackenzie Financial Corp bought a new position in shares of Ginkgo Bioworks during the 2nd quarter valued at about $251,000. AQR Capital Management LLC acquired a new position in shares of Ginkgo Bioworks in the 2nd quarter valued at approximately $3,391,000. Finally, Benjamin F. Edwards & Company Inc. increased its stake in Ginkgo Bioworks by 1,606.9% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 234,836 shares of the company’s stock worth $79,000 after purchasing an additional 221,078 shares in the last quarter. Institutional investors and hedge funds own 78.63% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on DNA. BTIG Research upped their price target on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the company a “sell” rating in a report on Friday, August 23rd. The Goldman Sachs Group reduced their target price on shares of Ginkgo Bioworks from $0.80 to $0.30 and set a “sell” rating for the company in a research note on Tuesday, July 9th. Finally, TD Cowen lifted their price target on Ginkgo Bioworks from $3.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, September 20th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.16.

Ginkgo Bioworks Trading Up 2.8 %

Ginkgo Bioworks stock opened at $8.16 on Friday. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $5.26 and a 1-year high of $75.20. The company has a fifty day simple moving average of $7.51. The company has a market capitalization of $18.04 billion, a P/E ratio of -18.55 and a beta of 1.10.

Ginkgo Bioworks (NYSE:DNA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($3.20) earnings per share for the quarter, meeting the consensus estimate of ($3.20). The company had revenue of $56.21 million during the quarter, compared to analysts’ expectations of $41.46 million. Ginkgo Bioworks had a negative return on equity of 63.09% and a negative net margin of 486.98%. As a group, analysts predict that Ginkgo Bioworks Holdings, Inc. will post -12.6 earnings per share for the current fiscal year.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.